Kailera Therapeutics (KLRA) Company presentation summary

Strategic focus and pipeline overview

• Emphasis on obesity as a chronic disease affecting over 1 billion people globally, with a diversified GLP-1-based pipeline targeting critical unmet needs through both injectable and oral therapies.

• Four clinical-stage programs: ribupatide injection, ribupatide oral, KAI-7535 (oral small molecule), and KAI-4729 (injectable tri-agonist), each designed for specific patient profiles and market segments.

• Partnership with Hengrui accelerates global development, provides access to novel therapies, and supplements manufacturing capacity.

• Management and board have extensive experience in developing and commercializing metabolic disease therapies, supported by $1.6B+ raised since launch.

• Cash on hand, including IPO proceeds, expected to fund operations into mid-2028.

Clinical progress and efficacy highlights

• Initiated five late-stage global obesity clinical trials, including Phase 3 and Phase 2b studies for ribupatide and KAI-7535.

• Ribupatide injection achieved 23.6% mean weight loss at 36 weeks (8 mg dose) in Phase 2, with no observed plateau and favorable tolerability.

• Ribupatide oral showed up to 12.1% mean weight loss at 26 weeks in Phase 2, with low gastrointestinal adverse event rates.

• KAI-7535 demonstrated up to 15% weight loss at 36 weeks in post-hoc analysis of Phase 2, with class-like tolerability and no liver safety concerns.

• KAI-4729 showed up to 16% mean weight loss at 12 weeks in Phase 1, with dose-dependent liver fat reduction and a safety profile consistent with GLP-1-based treatments.

Market opportunity and patient segmentation

• By 2030, over 60 million US adults are expected to have BMI 35+, representing a significant unmet need for higher efficacy weight loss therapies.

• Ribupatide injection is positioned as a leading option for patients with BMI 35+, outperforming current high-efficacy injectables in clinical trials.

• Oral therapies, projected to comprise ~20% of the obesity market by 2030, are being developed to address patients with lower BMI and those seeking improved tolerability.

• Differentiated efficacy and tolerability profiles are expected to drive adoption in both injectable and oral segments.